Najajreh Yousef, Kasparkova Jana, Marini Victoria, Gibson Dan, Brabec Viktor
Department of Medicinal Chemistry and Natural Products, School of Pharmacy, The Hebrew University of Jerusalem, P.O.Box 12065, Jerusalem, 91120, Israel.
J Biol Inorg Chem. 2005 Nov;10(7):722-31. doi: 10.1007/s00775-005-0024-2. Epub 2005 Nov 8.
trans-Diaminedicholoroplatinum(II) complexes with one planar and one non-planar heterocyclic amine ligand were designed as new potential antitumor drugs. The X-ray crystallographic structures of trans-[PtCl2(4-picoline)(piperidine)] and trans-[PtCl2(4-picoline)(piperazine)].HCl revealed that the piperidine and piperazine ligands bind to the platinum through the equatorial position and that the ligands adopt the chair conformation. The nonplatinated amine of the piperazine can form hydrogen bonds with atoms that are approximately 7.5 A away from the Pt binding site. DNA is considered a major pharmacological target of platinum compounds. Hence, to expand the database correlating structural features of platinum compounds and DNA distortions induced by these compounds, which may facilitate identification of more effective anticancer platinum drugs, we describe the DNA binding mode in a cell-free medium of trans-[PtCl2(4-picoline)(piperidine)] and trans-[PtCl2(4-picoline)(piperazine)].HCl. Interestingly, the overall impact of the replacement of the second ammine group in transplatin by the heterocyclic ligands appears to change the character of the global conformational changes induced in DNA towards that induced by cisplatin. The clinical ineffectiveness of the parent transplatin has been proposed to be also associated with its reduced capability to form bifunctional adducts in double-helical DNA. The results of the present work support the view that replacement of both ammine groups of transplatin by heterocyclic ligands enhances cytotoxicity probably due to the marked enhancement of the stability of intrastrand cross-links in double-helical DNA.
设计了具有一个平面和一个非平面杂环胺配体的反式二氯二胺铂(II)配合物作为新型潜在抗肿瘤药物。反式-[PtCl₂(4-甲基吡啶)(哌啶)]和反式-[PtCl₂(4-甲基吡啶)(哌嗪)]·HCl的X射线晶体结构表明,哌啶和哌嗪配体通过赤道位置与铂结合,且配体采取椅式构象。哌嗪的未铂化胺可与距离铂结合位点约7.5 Å的原子形成氢键。DNA被认为是铂化合物的主要药理学靶点。因此,为了扩展将铂化合物的结构特征与这些化合物诱导的DNA畸变相关联的数据库,这可能有助于鉴定更有效的抗癌铂药物,我们描述了反式-[PtCl₂(4-甲基吡啶)(哌啶)]和反式-[PtCl₂(4-甲基吡啶)(哌嗪)]·HCl在无细胞培养基中的DNA结合模式。有趣的是,用杂环配体取代反铂中的第二个胺基的总体影响似乎改变了DNA中诱导的全局构象变化的特征,使其朝着顺铂诱导的方向转变。已提出母体反铂的临床无效性也与其在双螺旋DNA中形成双功能加合物的能力降低有关。本研究结果支持这样一种观点,即用杂环配体取代反铂的两个胺基可能会增强细胞毒性,这可能是由于双螺旋DNA链内交联稳定性的显著增强。